Test blood test for a specific type of pancreatic cancer cell
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You have pancreatic cancer that has spread to distant organs (remote metastases)
- You have not started any cancer treatment yet, and can begin first-line treatment
- You can give your consent to join the study (or your legal consent is available)
- You are able and willing to follow the study monitoring steps (you’re not expected to have major follow-up difficulties)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study uses stored blood samples from people at higher risk for pancreatic cancer (due to family history or certain pancreatic cysts) to see if a simple blood test can detect the disease early or help monitor it over time.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.